Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer

Inclusion Criteria

• •Elected to undergo interstitial brachytherapy as part of conventional treatment for renal cell carcinoma
• •Biopsy proven renal cell carcinoma
• •No definitive evidence of locally advanced (nodal or tumor thrombus) or distant (metastatic) disease
• •Lesion size (maximal dimension) of 4 to 10 cm
• •Patient not a candidate for curative surgery (unwilling or unable to pursue surgery)
• •Lesion cannot be reliably treated with ablative techniques
• •Entire lesion able to be treated adequately by brachytherapy per radiation oncologist
• •Tumor predominantly solid (\~ \> 80%)
• •Lesion that has been observed for \>= 6 months with demonstrable growth rate anticipated to be \>= 4 mm/year by same imaging modality
• •Renal tumor that is amenable to percutaneous access for interstitial renal brachytherapy (Institutional Review Board \[IRB\])
• •Hemoglobin \> 9
• •Absolute neutrophil count (ANC) \>= 1500/uL (microliter)
• •Platelets \>= 100,000/uL
• •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3.0 upper limit of normal (ULN)
• •Total bilirubin =\< ULN
• •A competent immune system
• •Estimated glomerular filtration rate (eGFR) \>= 30
• •Good performance status (Eastern Cooperative Oncology Group \[ECOG\]) \< 2
• •Understanding and willingness to provide consent
• •No prior systemic treatment for kidney cancer
• •Women of childbearing potential must have negative pregnancy test at start of therapy